High-grade Gliomas Clinical Trial
Official title:
Efficacy and Tolerability of Cisplatin Plus Alternating Weekly Temozolomide in Recurrent High-grade Gliomas: A Single-arm Prospective Phase II Clinical Study
Currently, the prognosis of recurrent high-grade gliomas is still dismal with no standard
treatment protocol established. Cisplatin (CDDP), recommended by National Comprehensive
Cancer Network (NCCN) as a chemotherapeutic agent in salvage treatment for recurrent
high-grade gliomas, was shown to reduce O6-alkylguanine DNA-alkyl transferase (AGAT) activity
and potentially capable of enhancing the antitumor effects of temozolomide (TMZ). Compared to
the standard 5-day TMZ regimen, alternating weekly regimen that deliver more prolonged
exposure of TMZ may lead to higher cumulative doses, and may deplete more O6-methylguanine
DNA methyltransferase (MGMT), thus reducing the resistance of tumor cells to TMZ.
The investigators therefore initiate a single-arm Phase II study to evaluate the efficacy and
tolerability of CDDP plus alternating weekly TMZ regimen in patients with recurrent
high-grade gliomas.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00393094 -
Bevacizumab and Irinotecan to Treat Brain Tumors
|
Phase 2 | |
| Recruiting |
NCT03904628 -
Phase I Clinical Study of Oral TG02 Capsule in the Treatment of Recurrent / Progressive High-grade Glioma Patients
|
Phase 1 | |
| Recruiting |
NCT04253873 -
Clinical Study of Apatinib Combined With Temozolomide in the Treatment of Uncontrolled or Repeated High-grade Gliomas
|
Phase 2 |